miR-335 mimic

miR-335 mimic is a research-stage, unapproved synthetic double-stranded RNA oligonucleotide (microRNA mimic) that reproduces the activity of endogenous microRNA-335. It functions as an RNA therapeutic (miRNA replacement) by binding to the 3'UTR of target mRNAs and repressing their translation or inducing their degradation. In preclinical models of cerebral ischemia/stroke, the mimic targets hypoxia-inducible factor 1-alpha (HIF-1α) to reduce infarct volume when administered early after middle cervical artery occlusion. In various cancer models, it acts as a tumor suppressor by targeting Rho-associated coiled-coil containing protein kinase 1 (ROCK1), paired box protein Pax-6 (PAX6), and collagen alpha-1(XI) chain (COL11A1). In other settings, it targets myocyte-specific enhancer factor 2D (MEF2D) in gallbladder carcinoma, thrombospondin 1 (THBS1) in lung epithelial fibrosis, and exocytotic proteins (such as SNAP25, STXBP1, and Synaptotagmin-11) in pancreatic beta cells to regulate glucose-stimulated insulin secretion. The mimic is used strictly as a preclinical research reagent and has not been evaluated in clinical trials.

Other names

microRNA-335 mimicmicroRNA335 mimicmicroRNA 335 mimicmiR-335-3p mimicmiR335-3p mimicmiR 335-3p mimicmiR-335-5p mimicmiR335-5p mimicmiR 335-5p mimicrno-miR-335 mimicrno-miR335 mimicrno-miR 335 mimic